Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine
| Autor: | Asisa Volz, Ron A. M. Fouchier, Guus F. Rimmelzwaan, Michael H. Lehmann, Marco Goeijenbier, Heidi L. M. De Gruyter, Fleur M. Moesker, Albert D. M. E. Osterhaus, David A. M. C. van de Vijver, Gerd Sutter, Gerrie de Mutsert, Joost H. C. M. Kreijtz, Lennert W. J. van den Dries, Simone Goeijenbier, Eric C. M. van Gorp |
|---|---|
| Přispěvatelé: | Virology |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty H5N1 vaccine Adolescent Drug-Related Side Effects and Adverse Reactions Influenza vaccine viruses Genetic Vectors Hemagglutinin Glycoproteins Influenza Virus Vaccinia virus medicine.disease_cause Antibodies Viral complex mixtures Injections Intramuscular chemistry.chemical_compound Young Adult Double-Blind Method SDG 3 - Good Health and Well-being Internal medicine Clinical endpoint medicine Influenza A virus Animals Humans Adverse effect Drug Carriers Vaccines Synthetic Influenza A Virus H5N1 Subtype business.industry Immunogenicity virus diseases Hemagglutination Inhibition Tests Healthy Volunteers Infectious Diseases chemistry Influenza Vaccines Immunology Chills Female medicine.symptom Vaccinia business |
| Zdroj: | The Lancet Infectious Diseases, 14(12), 1196-207. Lancet Publishing Group |
| ISSN: | 1473-3099 |
| DOI: | 10.1016/s1473-3099(14)70963-6 |
| Popis: | BACKGROUND: Modified vaccinia virus Ankara (MVA) is a promising viral vector platform for the development of an H5N1 influenza vaccine. Preclinical assessment of MVA-based H5N1 vaccines showed their immunogenicity and safety in different animal models. We aimed to assess the safety and immunogenicity of the MVA-haemagglutinin-based H5N1 vaccine MVA-H5-sfMR in healthy individuals.METHODS: In a single-centre, double-blind phase 1/2a study, young volunteers (aged 18-28 years) were randomly assigned with a computer-generated list in equal numbers to one of eight groups and were given one injection or two injections intramuscularly at an interval of 4 weeks of a standard dose (10(8) plaque forming units [pfu]) or a ten times lower dose (10(7) pfu) of the MVA-H5-sfMR (vector encoding the haemagglutinin gene of influenza A/Vietnam/1194/2004 virus [H5N1 subtype]) or MVA-F6-sfMR (empty vector) vaccine. Volunteers and physicians who examined and administered the vaccine were masked to vaccine assignment. Individuals who received the MVA-H5-sfMR vaccine were eligible for a booster immunisation 1 year after the first immunisation. Primary endpoint was safety. Secondary outcome was immunogenicity. The trial is registered with the Dutch Trial Register, number NTR3401.FINDINGS: 79 of 80 individuals who were enrolled completed the study. No serious adverse events were identified. 11 individuals reported severe headache and lightheadedness, erythema nodosum, respiratory illness (accompanied by influenza-like symptoms), sore throat, or injection-site reaction. Most of the volunteers had one or more local (itch, pain, redness, and swelling) and systemic reactions (rise in body temperature, headache, myalgia, arthralgia, chills, malaise, and fatigue) after the first, second, and booster immunisations. Individuals who received the 10(7) dose had fewer systemic reactions. The MVA-H5-sfMR vaccine at 10(8) pfu induced significantly higher antibody responses after one and two immunisations than did 10(7) pfu when assessed with haemagglutination inhibition geometric mean titre at 8 weeks against H5N1 A/Vietnam/1194/2004 (30·2 [SD 3·8] vs 9·2 [2·3] and 108·1 [2·4] vs 15·8 [3·2]). 27 of 39 eligible individuals were enrolled in the booster immunisation study. A single shot of MVA-H5-sfMR 10(8) pfu prime immunisation resulted in higher antibody responses after the booster immunisation than did two shots of MVA-H5-sfMR at the ten times lower dose.INTERPRETATION: The MVA-based H5N1 vaccine was well tolerated and immunogenic and therefore the vaccine candidates arising from the MVA platform hold great promise for rapid development in response to a future influenza pandemic threat. However, the immunogenicity of this vaccine needs to be compared with conventional H5N1 inactivated non-adjuvanted vaccine candidates in head-to-head clinical trials.FUNDING: European Research Council. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|